In molecular docking, EGFR and MAPK1 were used as receptors, and the active ingredients, quercetin, 17-β-estradiol, ursolic acid, and daidzein, were used as ligands for docking to verify the potential active components and targets of XHP on pancreatic cancer (Table 3 and Figure 9). Here, EGFR is linked to pancreatic neoplasm.